Cosmos Holdings (COSM) AI Stock Analysis

• Market Cap: $12.48M
• Dividend Yield: N/A
• Average Volume (3M): 250.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.84
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 29,241,741
• 10 Day Avg. Volume: 147,260
• 30 Day Avg. Volume: 250,177
• PEG Ratio: 0.02
• Price to Book (P/B): 0.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.58
• Enterprise Value/Market Cap: 36.55K
• Enterprise Value/Revenue: 2.07K
• Enterprise Value/Gross Profit: 90.76K
• Enterprise Value/Ebitda: -7.15K
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: $0.50 ▲(16.28%Upside)

The overall stock score for Cosmos Holdings reflects significant financial and valuation challenges. Financial performance is the most critical factor, showing persistent losses and negative cash flows. Technical analysis offers a slightly more positive outlook, but valuation remains weak with negative P/E and no dividend yield. Addressing financial inefficiencies is crucial for improving the stock's prospects.

Cosmos Holdings Business Overview & Revenue Model

Company Description

Cosmos Holdings Inc. is a multinational healthcare group operating primarily in the pharmaceutical sector. The company focuses on the research, development, and distribution of pharmaceutical products, including branded and generic medicines, nutraceuticals, and over-the-counter products. With operations spanning various countries, Cosmos Holdings aims to improve health and wellness outcomes through an integrated approach to healthcare delivery.

How the Company Makes Money

Cosmos Holdings generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is centered around the distribution of branded and generic medications to pharmacies, hospitals, and clinics. In addition to its core pharmaceutical offerings, Cosmos Holdings also engages in the sale of nutraceuticals and other health-related products. Strategic partnerships with healthcare providers and distribution networks play a crucial role in broadening the company's market reach and enhancing its earnings potential. By leveraging its extensive distribution network and product portfolio, Cosmos Holdings continues to expand its presence in the global healthcare market.

Cosmos Holdings Financial Statement Overview

Summary

Cosmos Holdings faces significant financial hurdles with persistent net losses, shrinking revenue, and negative cash flows. While there are signs of reducing debt, the company's financial health remains strained by operational inefficiencies and a heavy reliance on liabilities.

Income Statement

Cosmos Holdings' income statement reveals challenges in profitability, with consistent net losses and negative EBIT and EBITDA margins over recent periods. The TTM data shows a slight reduction in revenue, indicating a -1.60% revenue growth rate compared to the previous annual period. Despite some improvement in gross profit margin over the TTM period, the negative net profit margin and declining revenue indicate struggles in operational efficiency and market position.

Balance Sheet

The balance sheet of Cosmos Holdings shows moderate financial stability with a debt-to-equity ratio stabilizing as stockholders' equity increases. However, high total liabilities and low equity ratios reflect potential solvency concerns. The company has reduced total debt significantly over the TTM period, but the equity ratio remains weak, indicating a heavy reliance on liabilities.

Cash Flow

Cosmos Holdings' cash flow statement highlights ongoing liquidity challenges, with negative free cash flow and operating cash flow over recent periods. The TTM shows a negative free cash flow growth rate of approximately 30.05% compared to the previous year, indicating inefficiencies in cash generation. The operating cash flow to net income ratio remains negative, underscoring persistent cash burn issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	53.55M	54.43M	53.38M	50.35M	56.24M	55.41M
Gross Profit	5.03M	4.31M	4.35M	5.96M	8.33M	8.06M
EBITDA	-12.52M	-13.92M	-17.06M	-8.90M	-3.82M	4.39M
Net Income	-15.13M	-16.18M	-18.54M	-13.83M	-7.96M	820.79K
Balance Sheet
Total Assets	57.19M	54.31M	66.01M	68.04M	49.43M	43.84M
Cash, Cash Equivalents and Short-Term Investments	768.16K	336.25K	3.85M	20.76M	293.18K	851.19K
Total Debt	5.54M	11.82M	12.42M	12.03M	27.12M	32.04M
Total Liabilities	31.24M	29.78M	29.97M	28.38M	45.05M	48.01M
Stockholders Equity	25.95M	24.53M	36.04M	39.66M	4.38M	-4.16M
Cash Flow
Free Cash Flow	-5.69M	-8.14M	-24.80M	-15.25M	-7.99M	-11.62M
Operating Cash Flow	-4.49M	-7.72M	-15.64M	-14.87M	-7.10M	-11.50M
Investing Cash Flow	-931.79K	-798.27K	-13.76M	-21.50K	-826.82K	-117.74K
Financing Cash Flow	5.40M	5.05M	12.69M	35.05M	7.27M	12.46M

Cosmos Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COSM, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.45, below the 50-day MA of 0.44, and below the 200-day MA of 0.62, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.98 is Neutral, neither overbought nor oversold. The STOCH value of 41.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COSM.

Cosmos Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	60 Neutral	$12.96M	―	3.29%	―	-26.17%	―
Sector *	60 Neutral	HK$15.14B	5.55	-7.43%	4.45%	11.60%	-21.06%
COSM	47 Neutral	$12.48M	―	-58.30%	―	―	―
TXMD	47 Neutral	$12.96M	―	-7.72%	―	35.25%	81.05%
BFRI	46 Neutral	$5.68M	―	-384.98%	―	14.27%	87.31%
FLGC	42 Neutral	$13.77M	―	-336.65%	―	-28.78%	86.97%